Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8100631rdf:typepubmed:Citationlld:pubmed
pubmed-article:8100631lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:8100631lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:8100631lifeskim:mentionsumls-concept:C0221102lld:lifeskim
pubmed-article:8100631lifeskim:mentionsumls-concept:C0021853lld:lifeskim
pubmed-article:8100631lifeskim:mentionsumls-concept:C0001645lld:lifeskim
pubmed-article:8100631lifeskim:mentionsumls-concept:C0021826lld:lifeskim
pubmed-article:8100631lifeskim:mentionsumls-concept:C0750502lld:lifeskim
pubmed-article:8100631lifeskim:mentionsumls-concept:C0069942lld:lifeskim
pubmed-article:8100631lifeskim:mentionsumls-concept:C1512045lld:lifeskim
pubmed-article:8100631pubmed:issue5lld:pubmed
pubmed-article:8100631pubmed:dateCreated1993-8-5lld:pubmed
pubmed-article:8100631pubmed:abstractTextThe elimination of [3H]pafenolol and metabolites was investigated in fasted and fed rats. Separate groups received intravenous doses (0.3 and 3.0 mumol/kg) and oral doses (1 and 25 mumol/kg). After iv administration of pafenolol, the excretion of unchanged drug into urine and feces was about 50 and 25-30% of the given dose, respectively. The predominating mechanism for the excretion of pafenolol into feces was intestinal excretion (exsorption) directly from blood into gut lumen, since only about 3% of a given iv dose was recovered as pafenolol in the bile. When the oral dose was raised from 1 to 25 mumol/kg, the mean (+/- SD) bioavailability, calculated from urine data, increased from 14 +/- 9 to 30 +/- 11% (P < 0.05) in the starved rats and from 14 +/- 3 to 16 +/- 3% in the fed animals. In parallel, the fraction absorbed from the gut (fa) increased from 19 +/- 9 to 31 +/- 10% in the starved rats and from 16 +/- 4 to 19 +/- 5% in the fed animals, respectively. This indicates that the low bioavailability is due primarily to poor intestinal uptake.lld:pubmed
pubmed-article:8100631pubmed:languageenglld:pubmed
pubmed-article:8100631pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8100631pubmed:citationSubsetIMlld:pubmed
pubmed-article:8100631pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8100631pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8100631pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8100631pubmed:statusMEDLINElld:pubmed
pubmed-article:8100631pubmed:monthMaylld:pubmed
pubmed-article:8100631pubmed:issn0724-8741lld:pubmed
pubmed-article:8100631pubmed:authorpubmed-author:RegårdhC GCGlld:pubmed
pubmed-article:8100631pubmed:authorpubmed-author:LennernäsHHlld:pubmed
pubmed-article:8100631pubmed:issnTypePrintlld:pubmed
pubmed-article:8100631pubmed:volume10lld:pubmed
pubmed-article:8100631pubmed:ownerNLMlld:pubmed
pubmed-article:8100631pubmed:authorsCompleteYlld:pubmed
pubmed-article:8100631pubmed:pagination727-31lld:pubmed
pubmed-article:8100631pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:8100631pubmed:meshHeadingpubmed-meshheading:8100631-...lld:pubmed
pubmed-article:8100631pubmed:meshHeadingpubmed-meshheading:8100631-...lld:pubmed
pubmed-article:8100631pubmed:meshHeadingpubmed-meshheading:8100631-...lld:pubmed
pubmed-article:8100631pubmed:meshHeadingpubmed-meshheading:8100631-...lld:pubmed
pubmed-article:8100631pubmed:meshHeadingpubmed-meshheading:8100631-...lld:pubmed
pubmed-article:8100631pubmed:meshHeadingpubmed-meshheading:8100631-...lld:pubmed
pubmed-article:8100631pubmed:meshHeadingpubmed-meshheading:8100631-...lld:pubmed
pubmed-article:8100631pubmed:meshHeadingpubmed-meshheading:8100631-...lld:pubmed
pubmed-article:8100631pubmed:meshHeadingpubmed-meshheading:8100631-...lld:pubmed
pubmed-article:8100631pubmed:meshHeadingpubmed-meshheading:8100631-...lld:pubmed
pubmed-article:8100631pubmed:meshHeadingpubmed-meshheading:8100631-...lld:pubmed
pubmed-article:8100631pubmed:meshHeadingpubmed-meshheading:8100631-...lld:pubmed
pubmed-article:8100631pubmed:year1993lld:pubmed
pubmed-article:8100631pubmed:articleTitleDose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat.lld:pubmed
pubmed-article:8100631pubmed:affiliationDepartment of Biopharmaceutics and Pharmacokinetics, University of Uppsala, Sweden.lld:pubmed
pubmed-article:8100631pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8100631lld:pubmed